Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 86.16% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 41.79% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 95.61% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 38.36% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 64.03% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 45.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.15% |
| Mar 31, 2026 | 51.13% |
| Dec 31, 2025 | -50.73% |
| Sep 30, 2025 | 43.75% |
| Jun 30, 2025 | 89.72% |
| Mar 31, 2025 | 24.57% |
| Dec 31, 2024 | 48.15% |
| Sep 30, 2024 | 30.62% |
| Jun 30, 2024 | 8.76% |
| Mar 31, 2024 | 50.65% |
| Dec 31, 2023 | 11.37% |
| Sep 30, 2023 | 41.04% |
| Jun 30, 2023 | 53.27% |
| Mar 31, 2023 | 119.50% |
| Dec 31, 2022 | 59.46% |
| Sep 30, 2022 | 70.40% |
| Jun 30, 2022 | 59.46% |
| Mar 31, 2022 | 244.62% |
| Dec 31, 2021 | 218.46% |
| Sep 30, 2021 | 67.04% |